Patents by Inventor Peter Lenting

Peter Lenting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11085032
    Abstract: The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: August 10, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITA DI PERUGIA, AMERICAN UNIVERSITY OF BEIRUT, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Olivier Christophe, Cecile Denis, Peter Lenting
  • Patent number: 10655119
    Abstract: The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 441 and/or 448 of SEQ ID NO: 1 is mutated.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: May 19, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS—SUD
    Inventors: Olivier Christophe, Cecile Denis, Peter Lenting
  • Publication number: 20080096223
    Abstract: The invention relates to a method for distinguishing between different states or forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets, and/or to predict the progression of such a disease or disorder, said method comprising the steps of providing at least one biological sample obtained from a patient suffering from, or suspected to suffer from, at least one disease or disorder characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets and of determining the amount of activated vWF in said biological sample, in which the amount of activated vWF in the sample is representative for the different states or forms of the disease or disorder.
    Type: Application
    Filed: January 13, 2006
    Publication date: April 24, 2008
    Applicants: Ablynx N.V., UMC Utrecht Holding B.V.
    Inventors: Philip De Groot, Rob Fijnheer, Peter Lenting, Karen Silence